Jotbody (HK) Limited is an innovative biotechnology company founded in 2020, specializing in nanobody research and extracellular vesicles (EVs). It offers comprehensive services in nanobody discovery and engineering, including antigen design, humanization, and affinity maturation. With an advanced technology platform, the company provides high-quality research reagents and solutions to clients in over 20 countries.
Since 2014, Jotbody has been conducting EV research, collaborating with experts such as Dr. Minh Le from the National University of Singapore on EV modification for therapeutic applications. The company offers full support for EV research, from isolation and analysis to functionalization and CDMO solutions. In 2023, it was recognized by Forbes Asia in the “100 Companies to Watch” ranking.
Jotbody’s mission is to advance life sciences through innovations in nanobody and EV research, supporting both scientific exploration and therapeutic applications.